A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients with Relapsing-remitting Multiple Sclerosis.

Prior treatment

• Patients who have received or going to receive any of prohibited medications or treatments defined in the study protocol.

Other illness

• Patient with contraindications and/or severe hypersensitivity to corticosteroids including methylprednisolone or any of the excipients of study drug or etcs defined in the study protocol.
• Patient who has currently or history of any of medical conditions described in the study protocol.

Other

• Patient diagnosed with primary or secondary progressive MS.
• Patient diagnosed with MS for more than 15 years duration with an EDSS score ≤2.0 at Screening.
• Patient unable to complete or has a contraindication to an MRI

• Patient is male or female aged between 18 years and 55 years (both inclusive)
• Patient diagnosed as Multiple Sclerosis (MS) in accordance with the revised McDonald criteria (2017).
• Patient has evidence of recent MS activity as defined in the study protocol.
• Patient has neurological stability for ≥30 days.
• Patient with 0 to 6.0 (both inclusive) on the EDSS score.